Impact of Hydrophobic, Hydrophilic, and Mucus-Binding Motifs on the Therapeutic Potential of Ceftazidime Analogs for Pulmonary Administration
Authors:
- Kyle D. ApleyKAKyle D. Apley
- Stephanie N. JohnsonSJStephanie N. Johnson
- Jian QianJQJian Qian
- Indeewara MunasingheIMIndeewara Munasinghe
- Jennifer R. KlausJKJennifer R. Klaus
- Srilaxmi M. PatelSPSrilaxmi M. Patel
- Kathryn E. WoodsKWKathryn E. Woods
- Samalee BanerjeeSBSamalee Banerjee
- Josephine R. ChandlerJCJosephine R. Chandler
- Chamani PereraCPChamani Perera
- Nathalie BaumlinNBNathalie Baumlin
- Matthias SalatheMSMatthias Salathe
Open Access
- 11 February 2025
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 14 (2) , 177
Abstract
Background/Objectives: The pulmonary administration of antibiotics can be advantageous in treating pulmonary infections by promoting high intrapulmonary drug concentrations with reduced systemic exposure. However, limited benefits have been observed for pulmonary administration versus other administration routes due to its rapid clearance from the lung. Here, the effects of structural modifications on the epithelial permeability and antibacterial potency of a third-generation cephalosporin were investigated to improve the understanding of drug properties that promote intrapulmonary retention and how they may impact efficacy. Methods: Ceftazidime was modified by attaching 18 hydrophobic, hydrophilic, and mucus-binding motifs to the carboxylic acid distant from the beta-lactam by amidation. Epithelial permeability was investigated by drug transport assays using human bronchial epithelial air–liquid interface cultures. Antibacterial potency was determined by microtiter MIC assays with B. pseudomallei, P. aeruginosa, E. coli, and S. aureus. Results: A 40–50% reduction in the transepithelial transport rate was exhibited by two PEGylated ceftazidime analogs (mPEG8- and PEG5-pyrimidin-2-amine-ceftazidime) and n-butyl-ceftazidime. An increase in the transport rate was exhibited by four analogs bearing small and hydrophobic or negatively charged motifs (n-heptane-, phenyl ethyl-, glutamic acid-, and 4-propylthiophenyl boronic acid-ceftazidime). The antibacterial potency was reduced by ≥10-fold for most ceftazidime analogs against B. pseudomallei, P. aeruginosa, and E. coli but was retained by seven ceftazidime analogs primarily bearing hydrophobic motifs against S. aureus. Conclusions: The covalent conjugation of PEGs with MW > 300 Da reduced the epithelial permeability of ceftazidime, but these modifications severely reduced antibacterial activity. To improve the pulmonary retention of antibiotics with low membrane permeability, this work suggests future molecular engineering studies to explore high-molecular-weight prodrug strategies.Keywords
Funding Information
- Cystic Fibrosis Foundation (BERKLA20A0, R01 HL157942, P20GM113117, P30GM145499, S10RR024664, 1625923)
- National Institutes of Health (NIH) (BERKLA20A0, R01 HL157942, P20GM113117, P30GM145499, S10RR024664, 1625923)
- National Institute of General Medical Sciences of the NIH (BERKLA20A0, R01 HL157942, P20GM113117, P30GM145499, S10RR024664, 1625923)
- NIH Shared Instrumentation (BERKLA20A0, R01 HL157942, P20GM113117, P30GM145499, S10RR024664, 1625923)
- NSF Major Research Instrumentation award (BERKLA20A0, R01 HL157942, P20GM113117, P30GM145499, S10RR024664, 1625923)
This publication has 50 references indexed in Scilit:
- Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize ToxicityClinical Pharmacology & Therapeutics, 2021
- Sustained Pulmonary Delivery of a Water-Soluble Antibiotic Without Encapsulating CarriersPharmaceutical Research, 2015
- Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosaIntensive Care Medicine, 2009
- Synthesis of sulfonamide- and sulfonyl-phenylboronic acid-modified silica phases for boronate affinity chromatography at physiological pHAnalytical Biochemistry, 2008
- Air-Liquid Interface (ALI) Culture of Human Bronchial Epithelial Cell Monolayers as an in vitro Model for Airway Drug Transport StudiesJournal of Pharmaceutical Sciences, 2007
- Virtual Computational Chemistry Laboratory – Design and DescriptionJournal of Computer-Aided Molecular Design, 2005
- Pulmonary Absorption Rate and Bioavailability of Drugs in Vivo in Rats: Structure–Absorption Relationships and Physicochemical Profiling of Inhaled DrugsJournal of Pharmaceutical Sciences, 2003
- Mechanisms of macromolecule absorption by the lungsAdvanced Drug Delivery Reviews, 1996
- Formoterol: Pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilatorLife Sciences, 1993
- Corneal Penetration Behavior of β-Blocking Agents I: Physicochemical FactorsJournal of Pharmaceutical Sciences, 1983